For the first time since 2011, the biopharma industry failed to complete a single initial public offering in the month of January, signifying a slowdown that began in the fourth quarter of 2015. Even the dismal year of 2012 had at least one IPO in January, compared with two in 2013, six in 2014 and five last year.